- Home
- BTM vs TIL Comparison
BTM vs TIL Comparison
Compare BTM & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTM | TIL |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.8M | 74.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BTM | TIL |
|---|---|---|
| Price | $0.95 | $8.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.25 | ★ $125.00 |
| AVG Volume (30 Days) | ★ 1.1M | 69.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.87 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $5.67 |
| 52 Week High | $6.88 | $42.79 |
Technical Indicators
Market Signals| Indicator | BTM | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 41.43 | 59.35 |
| Support Level | $0.79 | $7.51 |
| Resistance Level | $0.90 | $7.87 |
| Average True Range (ATR) | 0.08 | 0.41 |
| MACD | 0.01 | 0.27 |
| Stochastic Oscillator | 50.51 | 91.03 |
Price Performance
Historical ComparisonAbout BTM Bitcoin Depot Inc.
Bitcoin Depot Inc owns and operates the widest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.